Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Cardiff Oncology Inc Onvansertib Clinical Trials Transcript

May 18, 2020 / NTS GMT
Release Date Price: €1.69 (+4.05%)
Neal Howard
Health Professional Radio - Moderator

Welcome to the program. I am your host, Neal Howard here on Health Professional Radio. We are going to have a conversation this evening with Dr. Mark Erlander. He is a CEO of Cardiff Oncology, and he is joining us here on Health Professional Radio to talk about their lead drug and to talk a little bit about clinical trials in colorectal cancer, acute myeloid leukemia, and prostate cancer. Welcome to the program, Dr. Erlanger, and thank you so much for taking the time.

Mark Erlander
Cardiff Oncology - CEO

Well, thank you, Neal. And please call me, Mark from going forward.

Yes.

Neal Howard
Health Professional Radio - Moderator

Alright. I'll do.

Mark Erlander
Cardiff Oncology - CEO

Yeah. Go ahead. Sorry.

Neal Howard
Health Professional Radio - Moderator

Well, I was just wanting you to tell us a little bit about yourself and then talk about what's being done there at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot